plasys 300® is a propietary blend from different botanical species to improve urinary symptoms related to prostate enlargement, improving men’s health and well-being containing phytosterols, (chiefly ß-sitosterol), and essential amino acids.
The phytosterols fraction acts as:
– 5α-reductase inhibitors, blocking the conversion of testosterone to dihydrotestosterone, reducing the enlargement of the prostate.
– α-blockers, preventing from urine leakage
The essential amino acids fraction acts:
– reducing urine frequency, urgency and improves nocturnia.
– strong anti-inflammatory plasys 300® inhibits the prostatic cancer cells proliferation (“in vitro” test)
As men age benign prostate glands may enlarge causing pressure on the urethra, resulting in weak urination, bladder emptying and downgrading their quality of life.
plasys 300® is effective in helping to reduce bothersome symptoms such as: nocturia, daytime frequency, and sensation of residual urine.1
plasys 300® extracts have shown significant improvements for prostate discomfort symptoms: ameliorates International Prostate Symptom Score (IPSS standard that scores the severity of LUTS), urinary flow rate (Qmax), and irritative and obstructive symptoms.2-3
Phytosterols have an anti-inflammatory effect that help inhibiting the synthesis of prostaglandins that accumulate in the prostate of men with BPH. These compounds are effective in relieving BPH symptoms, reducing nocturia, daytime frequency and sensation of residual urine, as well as being preventive from needed surgical intervention.4
Effects usually take 4 weeks to develop.5
Phytosterols act as 5-alpha-Reductase Inhibitors, chiefly ß-sitosterol (Figure 2), which is effective in relieving BPH symptoms (Berges et al., 2000).
Sterol fraction of plasys 300® induced anti-proliferation of human prostatic (PC-3) cells in a dose-dependent manner (Figure 3). At 10 μg/mL it inhibited cell proliferation by 50% whereas at its highest concentration, 50 μg/mL the inhibition held up at 65%
1. Elist. J. Urology. (2006) 67.
2. Berges, R. et al., Lancet. (1995) 345.
3. Dutkiewicz, S. International Urology and
Nephrology. (1996) 28.
4. Berges R. et al., BJU Int. (2000) 85.
5. Klippel, KF et al., J Urol. (1997) 80.
6. Wilt, TJ et al. BJU Int. (1999) 83.
7. Maderbacher, S. et al., EAU-EBU. (2007) 5.
8. Park, J. et al., JMH. (2008) 5.
9. EFSA Journal. (2010) 8 (10):1813.
10. Lowe. F. et al., Urology. (2001) 58.
11. Dreikorn, K. World J Urol. (2002) 19.
12. Wilt, TJ et al. Cochrane Library. (2011) 5.
13. Becker, H. Urologe. (1988) 28.
14. Nakase, K. et al., Jpn J Pharmacol. (1990) 53.
15. Cheng HJ et al., Acta Pharmacol Sin. (2002) 23.
16. Buck, AC. et al., Brit.J. Urol. (1989) 64.